Enoxaparin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
- Enoxaparin
- Enoxaparin: From Anticoagulation Therapy to Thrombophilia Due to Protein C Deficiency (Autosomal Recessive)
Enoxaparin: From Anticoagulation Therapy to Thrombophilia Due to Protein C Deficiency (Autosomal Recessive)
One-Sentence Summary
Enoxaparin is a well-established low molecular weight heparin (LMWH), widely used in clinical practice for the prevention and treatment of venous thromboembolism (VTE), deep vein thrombosis (DVT), and acute coronary syndromes. The TxGNN model predicts it may be effective for Thrombophilia Due to Protein C Deficiency, Autosomal Recessive (TxGNN global rank #3,398; score 99.58%). Currently, there are no registered clinical trials and no published literature directly addressing this specific indication, placing the evidence at Level L4 (mechanistic rationale only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | VTE prevention and treatment, DVT, acute coronary syndromes (established clinical use; no Philippines regulatory data on record) |
| Predicted New Indication | Thrombophilia Due to Protein C Deficiency, Autosomal Recessive |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L4 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Enoxaparin is a Low Molecular Weight Heparin (LMWH) whose primary anticoagulant mechanism involves enhancing Antithrombin III activity. This selectively inhibits Factor Xa (the drug’s dominant anti-Xa activity) and partially inhibits Factor IIa (thrombin), effectively interrupting the coagulation cascade and suppressing excessive thrombin generation. Detailed MOA data from DrugBank was not retrieved in this evidence pack cycle, but the pharmacology of Enoxaparin is well characterised in the biomedical literature.
Autosomal recessive Protein C deficiency (homozygous or compound heterozygous) represents one of the most catastrophic inherited thrombophilias. Because Protein C normally acts as a natural anticoagulant by inactivating Factor Va and Factor VIIIa, its complete absence eliminates this critical brake on the coagulation cascade. The result is uncontrolled thrombin generation, recurrent deep vein and arterial thrombosis, and — in neonates — life-threatening purpura fulminans. Enoxaparin directly compensates for this deficit downstream: by blocking Factor Xa, it interrupts the very pathway left unchecked by Protein C loss, making the mechanistic rationale exceptionally compelling (pathway: Protein C deficiency → uncontrolled FVa/FVIIIa → excess thrombin → thrombosis ← [Enoxaparin] anti-Xa ⊣ Xa → thrombin generation blocked).
A critical clinical caveat contextualises this prediction: the TxGNN model is confirming a mechanistically sound adjunctive role rather than identifying a novel first-line therapy. For the severe neonatal presentation (purpura fulminans), first-line treatment is Protein C concentrate or fresh frozen plasma (FFP) — providing direct replacement of the deficient protein. Enoxaparin’s established role is as an adjunctive or maintenance anticoagulant, particularly in less acute presentations, in older patients with milder phenotypes, or when Protein C concentrate is not available. This framing is important for clinical translation.
Clinical Trial Evidence
Currently no related clinical trials registered specifically for Enoxaparin in thrombophilia due to protein C deficiency, autosomal recessive.
Literature Evidence
Currently no related literature available specifically addressing Enoxaparin use in thrombophilia due to protein C deficiency, autosomal recessive.
Philippines Market Information
Enoxaparin currently holds no marketing authorizations in the Philippines. The drug is not registered with the FDA Philippines as of the data cut-off (2026-04-05). Any clinical use would require special compassionate use or importation procedures.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between Enoxaparin and autosomal recessive Protein C deficiency thrombophilia is scientifically sound and well-founded — the coagulation biology is unambiguous. However, the absence of any dedicated clinical trials or published literature for this specific indication, combined with the drug’s non-registered status in the Philippines, means there is insufficient evidence to advance to a formal repurposing programme at this stage.
To proceed, the following is needed:
- Retrieve safety data: Download the full prescribing information (SmPC or US PI) to populate key warnings, contraindications, and drug interactions — this is a blocking gap before any clinical safety assessment can proceed.
- Targeted literature review: Search for case series, observational cohort data, and existing haematology/thrombosis society guidelines on LMWH use in hereditary Protein C deficiency to determine whether published evidence already exists outside the queried databases.
- Clarify repurposing framing: Determine whether this constitutes a true novel indication or an extension of established LMWH use in rare hereditary thrombophilias — this affects regulatory pathway and evidence requirements.
- Rare disease epidemiology: Estimate the Philippines patient population affected by autosomal recessive Protein C deficiency to evaluate clinical unmet need and commercial feasibility.
- Regulatory pathway: If proceeding, assess the Philippines FDA orphan/rare disease designation framework and the pathway for registering an established drug in a rare haematological indication.
- Paediatric safety plan: Given that the most severe presentations occur in neonates and infants, any clinical programme must include a dedicated paediatric safety and dosing sub-plan.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.